Characteristics of patients initiating Spiriva Respimat in Asthma in the UK: a cross-sectional study based on the Clinical Practice Research Datalink

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/25683
• EU PAS number:
  EUPAS25682
• Study ID:
  25683
• Official title and acronym:
  Characteristics of patients initiating Spiriva Respimat in Asthma in the UK: a cross-sectional study based on the Clinical Practice Research Datalink
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This study is a cross-sectional, non-interventional study based on existing data (NISed). The UK CPRD data will be used to assess thecharacteristics of asthma patients who were prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC in the UK during the study period (September 2014-December 2017) enabling to assess potential channeling of prescribing to different patient populations.
• Study status:
  Planned

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned: 01/09/2018

Actual: 01/09/2018

Study start date

Planned: 23/10/2018

Date of final study report

Planned: 31/03/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable